SNMMI's communications staff is available to handle your inquiries, arrange interviews with experts, provide copies of research articles and more.
For assistance, please contact Rebecca Maxey, director of communications, at rmaxey@snmmi.org or (703) 652-6772.
SNMMI is dedicated to being the premier source of information on nuclear medicine and molecular imaging. The society's online newsroom provides reporters with the information needed to write articles and gain background information on the many topics related to nuclear medicine, molecular imaging and therapy.
SNMMI issues press releases on new research, society updates and industry news for members of the press. Check back frequently to see what's new with SNMMI.
View press releases on the latest research and news from SNMMI.
Please see Tab 6 for information about SNMMI's 2023 Annual Meeting.
Nuclear and molecular imaging are vital elements of today's medical practice, adding an additional dimension to diagnosis that can change the way diseases are understood and treated. Nuclear medicine therapies treat specific diseases, such as lymphoma or thyroid cancer, by allowing a high dose of medicine to be delivered directly to a tumor or problem area. SNMMI's fact sheets explain how nuclear medicine and molecular imaging can help diagnose and/or treat a wide range of diseases.
Interested in radiopharmaceutical therapy for cancer and other diseases? Visit our Therapy Central portal, or check out our nuclear medicine therapy infographic.
SNMMI publishes two peer-reviewed medical journals—The Journal of Nuclear Medicine (JNM) and The Journal of Nuclear Medicine Technology (JNMT)—which feature the latest in molecular imaging research. JNM and JNMT are the most widely read peer-reviewed publications in molecular imaging, nuclear medicine and allied disciplines.
Every month, JNM brings readers around the globe key research articles on theranostics, nuclear medicine therapy, and imaging of cancer, neurological disease, cardiological disease, and other disease as well as continuing education articles and updates on rapidly changing issues in practice and research.
Published quarterly, JNMT focuses on technology, quality assurance, radiation safety, and the clinical applications of nuclear medicine. Each issue features continuing education articles written by leading educators in nuclear medicine technology as well as news and updates on practice, licensure, and credentialing for nuclear medicine technologists. Practitioners from across the imaging sciences turn to JNMT for peer-reviewed information related to daily clinical practice.
SNMMI can connect you with subject-matter experts on a variety of topics who are ready to respond to tight deadlines. Contact Rebecca Maxey, director of communications, at rmaxey@snmmi.org or at (703) 652-6772, to set up an interview with SNMMI's leadership or with one of its many experts on oncology, brain disease, heart disease, radiopharmaceuticals, reimbursement and more.
SNMMI Leadership
SNMMI-TS Leadership
Join SNMMI on our social media networks to stay updated on the latest from the society and the nuclear medicine and molecular imaging field.
![]() |
![]() |
![]() |
![]() |
The SNMMI Annual Meeting is recognized as the premier educational, scientific, research, and networking event in nuclear medicine and molecular imaging. The four-day event, which generally takes place each June, provides physicians, technologists, pharmacists, laboratory professionals, and scientists with an in-depth view of the latest research and development in the field and the clinic.
The SNMMI 2023 Annual Meeting will take place June 24–27, 2023, at McCormick Place in Chicago, IL.
Leading molecular imaging and nuclear medicine physicians, radiologists, cardiologists, pharmacists, scientists, lab professionals, and technologists, representing the world's top medical and academic institutions and centers. The 2022 Annual Meeting attracted more than 6,700 registrants.
The 2023 Annual Meeting will feature an exceptional program highlighted by some of the hottest topics in nuclear medicine and molecular imaging, including a science pavilion featuring the latest scientific research, an interactive virtual exhibit hall, categorical seminars, satellite symposia, networking events, and more.
SNMMI offers free registration to accredited members of the press or writers who can supply a letter of assignment from a publication or media outlet. Registration provides access to all open educational sessions, the exhibit area, and press room.
Pre-registration is required. Members of the media should register by contacting Rebecca Maxey at rmaxey@snmmi.org or (703) 652-6772.
The SNMMI Press Office location will be posted here when available. An SNMMI press liaison will be present to handle media requests.
Hours:
Saturday, June 24 — 1:00−5:00 pm
Sunday, June 25 — 10:00 am−5:30 pm
Monday, June 26 — 10:00 am−5:30 pm
Tuesday, June 27 — 8:00 am−5:30 pm
Follow us on Twitter @SNM_MI for the latest updates from the meeting; our official hashtag is #SNMMI23.
Event details and program information will be available in early 2023 on the SNMMI website.
PSMA PET mapping of cancer recurrence in the prostate bed shows that current radiotherapy contouring guidelines—which determine the target areas for treatment—miss a significant number of lesions and may unnecessarily irradiate healthy tissues, according to a new study published ahead of print in JNM. Researchers are calling for redefinition of the guidelines to improve patient outcomes.
(Press Release)
A novel, palm-sized imaging modality that can visualize the distribution of medical radiopharmaceuticals with very fine resolution has been developed and successfully tested, according to research published in March JNM. Known as the lensless radiomicroscope, the instrument offers the same level of imaging performance as its closest imaging equivalent but comes with significantly larger field of view and costs less than $100.
(Press Release)
A new radiotracer, Ga-68 FAP-2286, has been found to be more effective than the most commonly used nuclear medicine cancer imaging radiotracer, F-18 FDG, according to a study published in JNM. Ga-68 FAP-2286 detected 100 percent of primary tumors across multiple cancer types as compared to F-18 FDG, which identified only 80 percent. Ga-68 FAP-2286 was also more effective in detecting lymph node metastases and distant metastases.
(Press Release)
SNMMI, along with more than 80 stakeholder organizations, supports and applauds the introduction of H.R. 1199, the Facilitating Innovative Nuclear Diagnostic (FIND) Act of 2023. The legislation will ensure patient access to innovative and effective diagnostic imaging.
(Press Release)
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.